What is Lucid Diagnostics Inc (LUCD) stock price today?

Lucid Diagnostics Inc (LUCD) currently trades at $1.07 per share. The stock has a market capitalization of $199.66M and a P/E ratio of —x.

Is LUCD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Lucid Diagnostics Inc has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -14.28.

What is Lucid Diagnostics Inc's revenue and earnings?

Lucid Diagnostics Inc has trailing twelve-month (TTM) revenue of $4.71M with profit margins of 0.00%. Earnings per share (EPS) is $-0.69.

Is Lucid Diagnostics Inc financially healthy?

Lucid Diagnostics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -14.28 places it in the distress.

LUCD

Lucid Diagnostics Inc

NASDAQ: LUCD · HEALTHCARE · MEDICAL DEVICES

$1.07

+3.88% today

Updated 2026-04-30

Market cap

$199.66M

P/E ratio

—

P/S ratio

42.43x

EPS (TTM)

$-0.69

Dividend yield

—

52W range

$1 – $2

Volume

0.8M

Market cap

$199.66M

P/E ratio

—

P/S ratio

42.43x

EPS (TTM)

$-0.69

Dividend yield

—

52W range

$1 – $2

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

4.5

Quality

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-14.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$4.10

+283.18%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 25.60% QoQ

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -14.28 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-12.63M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$377000.00	$2.43M	$4.35M	$4.71M	$4.71M
Net income	$-56.17M	$-52.67M	$-45.53M	$-58.01M	$-16.27M
EPS	—	—	—	—	$-0.69
Free cash flow	$-30.59M	$-33.04M	$-44.79M	$-46.49B	$-12.63M
Profit margin	-14,899.47%	-2,169.11%	-1,047.61%	-1,232.68%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LUCD	$199.66M	27	7.3	2.5	5.0	4.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Lucid Diagnostics Inc trades at $1.07. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -14.28, it sits in the distress. TTM revenue stands at $4.71M.

Frequently asked questions

What is Lucid Diagnostics Inc's stock price?

Lucid Diagnostics Inc (LUCD) trades at $1.07.

Is Lucid Diagnostics Inc overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Lucid Diagnostics Inc (LUCD)?

The analyst target price is $4.10, representing +283.2% upside from the current price of $1.07.

What is Lucid Diagnostics Inc's revenue?

TTM revenue is $4.71M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-14.28 — distress.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.luciddx.com

Quick metrics

P/S ratio42.43x

ROE-711.00%

Beta1.25

50D MA$1.29

200D MA$1.17

Shares out0.19B

Float0.13B

Short ratio—

Avg volume0.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LUCD vs LLY →LUCD vs JNJ →LUCD vs ABBV →Stock screener →